カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のハンター症候群治療市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Hunter Syndrome Therapeutic Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19402）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19402
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：92
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のハンター症候群治療市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ハンター症候群治療市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のハンター症候群治療の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ハンター症候群治療市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・静脈内、脳室内（ICV）

用途別セグメントは次のように区分されます。
・病院、診療所、その他

世界のハンター症候群治療市場の主要な市場プレーヤーは以下のとおりです。
・Takeda、Denali Therapeutics、ArmaGen、Inventiva、Green Cross Corp、CANbridge Life Sciences Ltd.、JCR Pharmaceuticals、REGENXBIO、Sangamo Therapeutics

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ハンター症候群治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なハンター症候群治療メーカーの企業概要、2019年～2022年までのハンター症候群治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なハンター症候群治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ハンター症候群治療の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのハンター症候群治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのハンター症候群治療市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびハンター症候群治療の産業チェーンを掲載しています。
・第13、14、15章では、ハンター症候群治療の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ハンター症候群治療の概要
- 種類別分析（2017年vs2021年vs2028年）：静脈内、脳室内（ICV）
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、その他
- 世界のハンター症候群治療市場規模・予測
- 世界のハンター症候群治療生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Takeda、Denali Therapeutics、ArmaGen、Inventiva、Green Cross Corp、CANbridge Life Sciences Ltd.、JCR Pharmaceuticals、REGENXBIO、Sangamo Therapeutics
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：静脈内、脳室内（ICV）
・用途別分析2017年-2028年：病院、診療所、その他
・ハンター症候群治療の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ハンター症候群治療のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ハンター症候群治療のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ハンター症候群治療の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ハンター症候群治療の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Hunter Syndrome Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Hunter Syndrome Therapeutic market size is estimated to be worth US$ 1062.2 million in 2021 and is forecast to a readjusted size of USD 1505.6 million by 2028 with a CAGR of 5.1% during review period. Hospital accounting for % of the Hunter Syndrome Therapeutic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Intravenous segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Hunter Syndrome Therapeutic include Takeda, Denali Therapeutics, ArmaGen, Inventiva, and Green Cross Corp, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Hunter Syndrome Therapeutic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Intravenous
Intracerebroventricular (ICV)
Market segment by Application can be divided into
Hospital
Clinic
Other
The key market players for global Hunter Syndrome Therapeutic market are listed below:
Takeda
Denali Therapeutics
ArmaGen
Inventiva
Green Cross Corp
CANbridge Life Sciences Ltd.
JCR Pharmaceuticals
REGENXBIO
Sangamo Therapeutics
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hunter Syndrome Therapeutic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hunter Syndrome Therapeutic, with price, sales, revenue and global market share of Hunter Syndrome Therapeutic from 2019 to 2022.
Chapter 3, the Hunter Syndrome Therapeutic competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hunter Syndrome Therapeutic breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Hunter Syndrome Therapeutic market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hunter Syndrome Therapeutic.
Chapter 13, 14, and 15, to describe Hunter Syndrome Therapeutic sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Hunter Syndrome Therapeutic Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hunter Syndrome Therapeutic Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Intravenous
1.2.3 Intracerebroventricular (ICV)
1.3 Market Analysis by Application
1.3.1 Overview: Global Hunter Syndrome Therapeutic Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Hunter Syndrome Therapeutic Market Size & Forecast
1.4.1 Global Hunter Syndrome Therapeutic Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Hunter Syndrome Therapeutic Sales in Volume (2017-2028)
1.4.3 Global Hunter Syndrome Therapeutic Price (2017-2028)
1.5 Global Hunter Syndrome Therapeutic Production Capacity Analysis
1.5.1 Global Hunter Syndrome Therapeutic Total Production Capacity (2017-2028)
1.5.2 Global Hunter Syndrome Therapeutic Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hunter Syndrome Therapeutic Market Drivers
1.6.2 Hunter Syndrome Therapeutic Market Restraints
1.6.3 Hunter Syndrome Therapeutic Trends Analysis
2 Manufacturers Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Hunter Syndrome Therapeutic Product and Services
2.1.4 Takeda Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Denali Therapeutics
2.2.1 Denali Therapeutics Details
2.2.2 Denali Therapeutics Major Business
2.2.3 Denali Therapeutics Hunter Syndrome Therapeutic Product and Services
2.2.4 Denali Therapeutics Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 ArmaGen
2.3.1 ArmaGen Details
2.3.2 ArmaGen Major Business
2.3.3 ArmaGen Hunter Syndrome Therapeutic Product and Services
2.3.4 ArmaGen Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Inventiva
2.4.1 Inventiva Details
2.4.2 Inventiva Major Business
2.4.3 Inventiva Hunter Syndrome Therapeutic Product and Services
2.4.4 Inventiva Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Green Cross Corp
2.5.1 Green Cross Corp Details
2.5.2 Green Cross Corp Major Business
2.5.3 Green Cross Corp Hunter Syndrome Therapeutic Product and Services
2.5.4 Green Cross Corp Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 CANbridge Life Sciences Ltd.
2.6.1 CANbridge Life Sciences Ltd. Details
2.6.2 CANbridge Life Sciences Ltd. Major Business
2.6.3 CANbridge Life Sciences Ltd. Hunter Syndrome Therapeutic Product and Services
2.6.4 CANbridge Life Sciences Ltd. Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 JCR Pharmaceuticals
2.7.1 JCR Pharmaceuticals Details
2.7.2 JCR Pharmaceuticals Major Business
2.7.3 JCR Pharmaceuticals Hunter Syndrome Therapeutic Product and Services
2.7.4 JCR Pharmaceuticals Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 REGENXBIO
2.8.1 REGENXBIO Details
2.8.2 REGENXBIO Major Business
2.8.3 REGENXBIO Hunter Syndrome Therapeutic Product and Services
2.8.4 REGENXBIO Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Sangamo Therapeutics
2.9.1 Sangamo Therapeutics Details
2.9.2 Sangamo Therapeutics Major Business
2.9.3 Sangamo Therapeutics Hunter Syndrome Therapeutic Product and Services
2.9.4 Sangamo Therapeutics Hunter Syndrome Therapeutic Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Hunter Syndrome Therapeutic Breakdown Data by Manufacturer
3.1 Global Hunter Syndrome Therapeutic Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Hunter Syndrome Therapeutic Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Hunter Syndrome Therapeutic
3.4 Market Concentration Rate
3.4.1 Top 3 Hunter Syndrome Therapeutic Manufacturer Market Share in 2021
3.4.2 Top 6 Hunter Syndrome Therapeutic Manufacturer Market Share in 2021
3.5 Global Hunter Syndrome Therapeutic Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Hunter Syndrome Therapeutic Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hunter Syndrome Therapeutic Market Size by Region
4.1.1 Global Hunter Syndrome Therapeutic Sales in Volume by Region (2017-2028)
4.1.2 Global Hunter Syndrome Therapeutic Revenue by Region (2017-2028)
4.2 North America Hunter Syndrome Therapeutic Revenue (2017-2028)
4.3 Europe Hunter Syndrome Therapeutic Revenue (2017-2028)
4.4 Asia-Pacific Hunter Syndrome Therapeutic Revenue (2017-2028)
4.5 South America Hunter Syndrome Therapeutic Revenue (2017-2028)
4.6 Middle East and Africa Hunter Syndrome Therapeutic Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Hunter Syndrome Therapeutic Sales in Volume by Type (2017-2028)
5.2 Global Hunter Syndrome Therapeutic Revenue by Type (2017-2028)
5.3 Global Hunter Syndrome Therapeutic Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Hunter Syndrome Therapeutic Sales in Volume by Application (2017-2028)
6.2 Global Hunter Syndrome Therapeutic Revenue by Application (2017-2028)
6.3 Global Hunter Syndrome Therapeutic Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Hunter Syndrome Therapeutic Sales by Type (2017-2028)
7.2 North America Hunter Syndrome Therapeutic Sales by Application (2017-2028)
7.3 North America Hunter Syndrome Therapeutic Market Size by Country
7.3.1 North America Hunter Syndrome Therapeutic Sales in Volume by Country (2017-2028)
7.3.2 North America Hunter Syndrome Therapeutic Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Hunter Syndrome Therapeutic Sales by Type (2017-2028)
8.2 Europe Hunter Syndrome Therapeutic Sales by Application (2017-2028)
8.3 Europe Hunter Syndrome Therapeutic Market Size by Country
8.3.1 Europe Hunter Syndrome Therapeutic Sales in Volume by Country (2017-2028)
8.3.2 Europe Hunter Syndrome Therapeutic Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Hunter Syndrome Therapeutic Sales by Type (2017-2028)
9.2 Asia-Pacific Hunter Syndrome Therapeutic Sales by Application (2017-2028)
9.3 Asia-Pacific Hunter Syndrome Therapeutic Market Size by Region
9.3.1 Asia-Pacific Hunter Syndrome Therapeutic Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Hunter Syndrome Therapeutic Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Hunter Syndrome Therapeutic Sales by Type (2017-2028)
10.2 South America Hunter Syndrome Therapeutic Sales by Application (2017-2028)
10.3 South America Hunter Syndrome Therapeutic Market Size by Country
10.3.1 South America Hunter Syndrome Therapeutic Sales in Volume by Country (2017-2028)
10.3.2 South America Hunter Syndrome Therapeutic Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hunter Syndrome Therapeutic Sales by Type (2017-2028)
11.2 Middle East & Africa Hunter Syndrome Therapeutic Sales by Application (2017-2028)
11.3 Middle East & Africa Hunter Syndrome Therapeutic Market Size by Country
11.3.1 Middle East & Africa Hunter Syndrome Therapeutic Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Hunter Syndrome Therapeutic Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Hunter Syndrome Therapeutic and Key Manufacturers
12.2 Manufacturing Costs Percentage of Hunter Syndrome Therapeutic
12.3 Hunter Syndrome Therapeutic Production Process
12.4 Hunter Syndrome Therapeutic Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Hunter Syndrome Therapeutic Typical Distributors
13.3 Hunter Syndrome Therapeutic Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Hunter Syndrome Therapeutic Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Hunter Syndrome Therapeutic Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Takeda Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Major Business
Table 5. Takeda Hunter Syndrome Therapeutic Product and Services
Table 6. Takeda Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Denali Therapeutics Basic Information, Manufacturing Base and Competitors
Table 8. Denali Therapeutics Major Business
Table 9. Denali Therapeutics Hunter Syndrome Therapeutic Product and Services
Table 10. Denali Therapeutics Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. ArmaGen Basic Information, Manufacturing Base and Competitors
Table 12. ArmaGen Major Business
Table 13. ArmaGen Hunter Syndrome Therapeutic Product and Services
Table 14. ArmaGen Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Inventiva Basic Information, Manufacturing Base and Competitors
Table 16. Inventiva Major Business
Table 17. Inventiva Hunter Syndrome Therapeutic Product and Services
Table 18. Inventiva Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Green Cross Corp Basic Information, Manufacturing Base and Competitors
Table 20. Green Cross Corp Major Business
Table 21. Green Cross Corp Hunter Syndrome Therapeutic Product and Services
Table 22. Green Cross Corp Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. CANbridge Life Sciences Ltd. Basic Information, Manufacturing Base and Competitors
Table 24. CANbridge Life Sciences Ltd. Major Business
Table 25. CANbridge Life Sciences Ltd. Hunter Syndrome Therapeutic Product and Services
Table 26. CANbridge Life Sciences Ltd. Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. JCR Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. JCR Pharmaceuticals Major Business
Table 29. JCR Pharmaceuticals Hunter Syndrome Therapeutic Product and Services
Table 30. JCR Pharmaceuticals Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. REGENXBIO Basic Information, Manufacturing Base and Competitors
Table 32. REGENXBIO Major Business
Table 33. REGENXBIO Hunter Syndrome Therapeutic Product and Services
Table 34. REGENXBIO Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Sangamo Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Sangamo Therapeutics Major Business
Table 37. Sangamo Therapeutics Hunter Syndrome Therapeutic Product and Services
Table 38. Sangamo Therapeutics Hunter Syndrome Therapeutic Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Hunter Syndrome Therapeutic Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global Hunter Syndrome Therapeutic Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Hunter Syndrome Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Hunter Syndrome Therapeutic Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Hunter Syndrome Therapeutic Production Site of Key Manufacturer
Table 44. Hunter Syndrome Therapeutic New Entrant and Capacity Expansion Plans
Table 45. Hunter Syndrome Therapeutic Mergers & Acquisitions in the Past Five Years
Table 46. Global Hunter Syndrome Therapeutic Sales by Region (2017-2022) & (K Units)
Table 47. Global Hunter Syndrome Therapeutic Sales by Region (2023-2028) & (K Units)
Table 48. Global Hunter Syndrome Therapeutic Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Hunter Syndrome Therapeutic Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 51. Global Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 52. Global Hunter Syndrome Therapeutic Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Hunter Syndrome Therapeutic Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Hunter Syndrome Therapeutic Price by Type (2017-2022) & (US$/Unit)
Table 55. Global Hunter Syndrome Therapeutic Price by Type (2023-2028) & (US$/Unit)
Table 56. Global Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 57. Global Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 58. Global Hunter Syndrome Therapeutic Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Hunter Syndrome Therapeutic Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Hunter Syndrome Therapeutic Price by Application (2017-2022) & (US$/Unit)
Table 61. Global Hunter Syndrome Therapeutic Price by Application (2023-2028) & (US$/Unit)
Table 62. North America Hunter Syndrome Therapeutic Sales by Country (2017-2022) & (K Units)
Table 63. North America Hunter Syndrome Therapeutic Sales by Country (2023-2028) & (K Units)
Table 64. North America Hunter Syndrome Therapeutic Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Hunter Syndrome Therapeutic Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 67. North America Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 68. North America Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 69. North America Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 70. Europe Hunter Syndrome Therapeutic Sales by Country (2017-2022) & (K Units)
Table 71. Europe Hunter Syndrome Therapeutic Sales by Country (2023-2028) & (K Units)
Table 72. Europe Hunter Syndrome Therapeutic Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Hunter Syndrome Therapeutic Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 75. Europe Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 76. Europe Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 77. Europe Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific Hunter Syndrome Therapeutic Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific Hunter Syndrome Therapeutic Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific Hunter Syndrome Therapeutic Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Hunter Syndrome Therapeutic Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 86. South America Hunter Syndrome Therapeutic Sales by Country (2017-2022) & (K Units)
Table 87. South America Hunter Syndrome Therapeutic Sales by Country (2023-2028) & (K Units)
Table 88. South America Hunter Syndrome Therapeutic Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Hunter Syndrome Therapeutic Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 91. South America Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 92. South America Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 93. South America Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa Hunter Syndrome Therapeutic Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa Hunter Syndrome Therapeutic Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa Hunter Syndrome Therapeutic Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Hunter Syndrome Therapeutic Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Hunter Syndrome Therapeutic Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa Hunter Syndrome Therapeutic Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa Hunter Syndrome Therapeutic Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa Hunter Syndrome Therapeutic Sales by Application (2023-2028) & (K Units)
Table 102. Hunter Syndrome Therapeutic Raw Material
Table 103. Key Manufacturers of Hunter Syndrome Therapeutic Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Hunter Syndrome Therapeutic Typical Distributors
Table 107. Hunter Syndrome Therapeutic Typical Customers
List of Figures
Figure 1. Hunter Syndrome Therapeutic Picture
Figure 2. Global Hunter Syndrome Therapeutic Revenue Market Share by Type in 2021
Figure 3. Intravenous
Figure 4. Intracerebroventricular (ICV)
Figure 5. Global Hunter Syndrome Therapeutic Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Other
Figure 9. Global Hunter Syndrome Therapeutic Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Hunter Syndrome Therapeutic Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Hunter Syndrome Therapeutic Sales (2017-2028) & (K Units)
Figure 12. Global Hunter Syndrome Therapeutic Price (2017-2028) & (US$/Unit)
Figure 13. Global Hunter Syndrome Therapeutic Production Capacity (2017-2028) & (K Units)
Figure 14. Global Hunter Syndrome Therapeutic Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Hunter Syndrome Therapeutic Market Drivers
Figure 16. Hunter Syndrome Therapeutic Market Restraints
Figure 17. Hunter Syndrome Therapeutic Market Trends
Figure 18. Global Hunter Syndrome Therapeutic Sales Market Share by Manufacturer in 2021
Figure 19. Global Hunter Syndrome Therapeutic Revenue Market Share by Manufacturer in 2021
Figure 20. Hunter Syndrome Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Hunter Syndrome Therapeutic Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Hunter Syndrome Therapeutic Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Hunter Syndrome Therapeutic Sales Market Share by Region (2017-2028)
Figure 24. Global Hunter Syndrome Therapeutic Revenue Market Share by Region (2017-2028)
Figure 25. North America Hunter Syndrome Therapeutic Revenue (2017-2028) & (USD Million)
Figure 26. Europe Hunter Syndrome Therapeutic Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Hunter Syndrome Therapeutic Revenue (2017-2028) & (USD Million)
Figure 28. South America Hunter Syndrome Therapeutic Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Hunter Syndrome Therapeutic Revenue (2017-2028) & (USD Million)
Figure 30. Global Hunter Syndrome Therapeutic Sales Market Share by Type (2017-2028)
Figure 31. Global Hunter Syndrome Therapeutic Revenue Market Share by Type (2017-2028)
Figure 32. Global Hunter Syndrome Therapeutic Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 34. Global Hunter Syndrome Therapeutic Revenue Market Share by Application (2017-2028)
Figure 35. Global Hunter Syndrome Therapeutic Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America Hunter Syndrome Therapeutic Sales Market Share by Type (2017-2028)
Figure 37. North America Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 38. North America Hunter Syndrome Therapeutic Sales Market Share by Country (2017-2028)
Figure 39. North America Hunter Syndrome Therapeutic Revenue Market Share by Country (2017-2028)
Figure 40. United States Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Hunter Syndrome Therapeutic Sales Market Share by Type (2017-2028)
Figure 44. Europe Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 45. Europe Hunter Syndrome Therapeutic Sales Market Share by Country (2017-2028)
Figure 46. Europe Hunter Syndrome Therapeutic Revenue Market Share by Country (2017-2028)
Figure 47. Germany Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Hunter Syndrome Therapeutic Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Hunter Syndrome Therapeutic Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Hunter Syndrome Therapeutic Revenue Market Share by Region (2017-2028)
Figure 56. China Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Hunter Syndrome Therapeutic Sales Market Share by Type (2017-2028)
Figure 63. South America Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 64. South America Hunter Syndrome Therapeutic Sales Market Share by Country (2017-2028)
Figure 65. South America Hunter Syndrome Therapeutic Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Hunter Syndrome Therapeutic Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Hunter Syndrome Therapeutic Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Hunter Syndrome Therapeutic Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Hunter Syndrome Therapeutic Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Hunter Syndrome Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Hunter Syndrome Therapeutic in 2021
Figure 77. Manufacturing Process Analysis of Hunter Syndrome Therapeutic
Figure 78. Hunter Syndrome Therapeutic Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ハンター症候群治療の世界市場 2022年-2026年
  • 世界の月経前症候群治療薬市場2022年：市場規模予測（～2028年）
  • 過敏性腸症候群治療薬のグローバル市場展望 2023年-2029年：IBS-D薬、IBS-C薬、その他
  • メンクス症候群のグローバル市場展望 2023年-2029年：遺伝子治療、銅注射療法
  • 世界のコンパートメント症候群モニタリング装置市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19402 )"世界のハンター症候群治療市場2022年：市場規模予測（～2028年）" (英文：Global Hunter Syndrome Therapeutic Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。